Literature DB >> 2715685

Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease.

C P Maury1, E Salo, P Pelkonen.   

Abstract

The mechanism of vascular injury in Kawasaki disease (KD) is unclear. Recent studies suggest a role for circulating antibodies that are cytotoxic for endothelial cell antigens inducible by cytokines. Tumor necrosis factor-alpha (TNF, cachectin) is a monocyte- or macrophage-derived cytokine that has an important role as an effector molecule in various inflammatory processes. To study the possible involvement of TNF in KD, we measured the levels of circulating TNF in 39 patients with KD at various stages of the disease by using a newly developed sensitive radioimmunoassay. The TNF levels in sera from the acute and subacute phases of the disease were significantly (p less than 0.001) higher than in sera taken in the convalescence phase or in sera from children without inflammatory disease. In all patients from whom serial samples were available, the TNF level was higher during the acute and subacute phases than during convalescence. Coronary aneurysms developed in four of the patients, and these patients were among those who had the highest levels of circulating TNF during the acute and subacute phase (51.1 +/- 13.6 pg/ml (mean +/- SD) vs 30.4 +/- 15.8 pg/ml in patients without coronary aneurysms; p less than 0.001). No differences in circulating TNF levels were observed between patients who received as treatment aspirin plus intravenous immunoglobulin and those who received aspirin alone. The results show that the levels of circulating TNF are increased in acute KD and support the hypothesis that this cytokine may be involved in the pathogenesis of the vascular injury in KD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715685

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  31 in total

Review 1.  [Cytokines and heart diseases. Attempt at an update].

Authors:  K Werdan
Journal:  Med Klin (Munich)       Date:  1997-07-15

2.  Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease.

Authors:  W B Breunis; M H Biezeveld; J Geissler; I M Kuipers; J Lam; J Ottenkamp; A Hutchinson; R Welch; S J Chanock; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

Review 3.  The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases.

Authors:  D Y Leung
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

Review 4.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

5.  Changes in renal sodium transport during a systemic inflammatory response.

Authors:  Michael Eisenhut
Journal:  Pediatr Nephrol       Date:  2006-08-01       Impact factor: 3.714

6.  Serum soluble CD4 and CD8 levels in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Tsuji; T Motohashi; K Okumura; K Yabuta
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

7.  Monitoring the acute phase response: comparison of tumour necrosis factor (cachectin) and C-reactive protein responses in inflammatory and infectious diseases.

Authors:  C P Maury
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

8.  Association of vascular endothelial growth factor C-634 g polymorphism in taiwanese children with Kawasaki disease.

Authors:  K-C Hsueh; Y-J Lin; J-S Chang; L Wan; Y-H Tsai; C-H Tsai; C-P Chen; F-J Tsai
Journal:  Pediatr Cardiol       Date:  2007-09-15       Impact factor: 1.655

9.  Cytokines predict coronary aneurysm formation in Kawasaki disease patients.

Authors:  C Y Lin; C C Lin; B Hwang; B N Chiang
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

10.  A functional polymorphism, rs28493229, in ITPKC and risk of Kawasaki disease: an integrated meta-analysis.

Authors:  Jiao Lou; Sanqing Xu; Li Zou; Rong Zhong; Ti Zhang; Yu Sun; Xuzai Lu; Li Liu; Chuanqi Li; Li Wang; Guanglian Xiong; Wei Wang; Fangqi Gong; Jing Wu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.